Gastrointestinal Cancer

The immune checkpoint inhibitor nivolumab demonstrated activity in patients with previously treated esophageal cancer.

Adding liposomal irinotecan to 5-fluorouracil and leucovorin reduced the risk of death by 25% for patients with metastatic pancreatic cancer following progression on a gemcitabine-based regimen.

Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.

Amitabh Chak, MD, professor of Medicine, Gastroenterology, Case Western Reserve University School of Medicine, discusses challenges with screening patients for Barrett's esophagus and esophageal cancer.

Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors.

Yelena Y. Janjigian, MD, discusses possible causes of the negative LOGiC trial results, HER2 as a driver in esophagogastric cancer, and what the future holds for lapatinib.

Pamela L. Kunz, MD, discusses several recent studies that shown promise for the treatment of pancreatic neuroendocrine tumors (NETs), as well as other ongoing trials investigating the potential of immunotherapies in NETs.

Jennifer Wu, MD, sheds light on TAS-102, as well as some emerging agents likely to play a role in the treatment of patients with colorectal cancer.

John L. Marshall, MD, discusses treatment advancements and other ongoing developments in colorectal cancer.

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the importance of genetic testing for colorectal cancer.

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer.

John Marshall, MD, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses curing colorectal cancer.

Contemporary efforts toward defining molecular subsets of colorectal cancer can potentially aid our ability to refine therapy and improve outcomes for patients with colorectal cancer.

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the potential for immunotherapy in colorectal cancer with mismatch repair deficiency.

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Researchers from United States and Ireland have formed a partnership to advance nanoparticle-based delivery systems that would not only drive sustained-release of cytotoxic agents, but also could improve penetration of these treatments within the tumor and allow them to continue working for days or weeks.

The FDA has granted a breakthrough therapy designation to pembrolizumab as a potential therapy for patients with microsatellite instability-high metastatic colorectal cancer.

The FDA has approved MM-398 (irinotecan liposome injection; Onivyde) in combination with 5-fluorouracil (5-FU) and leucovorin as a treatment for patients with metastatic pancreatic cancer following prior administration of a gemcitabine-based regimen.

Everolimus improved progression-free survival by 7.1 months compared with placebo in patients with lung/gastrointestinal (GI) neuroendocrine tumors, representing a 52% reduction in the risk of progression or death.

Leonard Saltz, MD, discusses antiangiogenesis and the use of VEGF inhibitors in colorectal cancer.